Clinical Trial Update: A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease [Phase 3]

View source ↗

Summary

Phase 3 trial update of Velaglucerase alfa (VPRIV) in Chinese children, adolescents, and adults with Type 1 Gaucher disease has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease

Drugs mentioned

• VPRIV (VELAGLUCERASE ALFA)

Snippet

Sponsor: Takeda | Conditions: Gaucher Disease | Phase 3 | Status: COMPLETED | Results posted: 2025-02-26